Q1 Earnings Forecast for CMPX Issued By HC Wainwright

Compass Therapeutics, Inc. (NASDAQ:CMPX) – Stock analysts at HC Wainwright issued their Q1 2025 earnings per share estimates for Compass Therapeutics in a research note issued on Thursday, February 27th. HC Wainwright analyst J. Pantginis expects that the company will post earnings of ($0.11) per share for the quarter. HC Wainwright currently has a “Buy” rating and a $10.00 target price on the stock. The consensus estimate for Compass Therapeutics’ current full-year earnings is ($0.36) per share. HC Wainwright also issued estimates for Compass Therapeutics’ Q2 2025 earnings at ($0.12) EPS, Q3 2025 earnings at ($0.13) EPS, Q4 2025 earnings at ($0.07) EPS and FY2028 earnings at $0.85 EPS.

A number of other brokerages have also weighed in on CMPX. Leerink Partnrs lowered Compass Therapeutics from a “strong-buy” rating to a “hold” rating in a report on Friday, November 15th. D. Boral Capital reissued a “buy” rating and set a $32.00 price target on shares of Compass Therapeutics in a research report on Tuesday, February 25th. Jefferies Financial Group upped their price objective on shares of Compass Therapeutics from $7.00 to $8.00 and gave the company a “buy” rating in a report on Monday, February 10th. Guggenheim initiated coverage on shares of Compass Therapeutics in a report on Monday, February 24th. They set a “buy” rating and a $12.00 target price for the company. Finally, Piper Sandler assumed coverage on shares of Compass Therapeutics in a research report on Wednesday, February 19th. They set an “overweight” rating and a $12.00 target price for the company. Two analysts have rated the stock with a hold rating and seven have issued a buy rating to the company. According to MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average target price of $11.38.

Compass Therapeutics Price Performance

NASDAQ CMPX opened at $2.78 on Monday. The stock’s fifty day moving average price is $2.64 and its 200 day moving average price is $1.98. Compass Therapeutics has a 1 year low of $0.77 and a 1 year high of $4.08. The company has a market cap of $382.50 million, a price-to-earnings ratio of -7.51 and a beta of 1.17.

Compass Therapeutics (NASDAQ:CMPX) last issued its quarterly earnings results on Thursday, February 27th. The company reported ($0.11) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.10) by ($0.01).

Institutional Trading of Compass Therapeutics

Several hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Enavate Sciences GP LLC acquired a new position in shares of Compass Therapeutics in the fourth quarter worth about $11,293,000. Tang Capital Management LLC increased its stake in shares of Compass Therapeutics by 225.4% in the 4th quarter. Tang Capital Management LLC now owns 5,900,000 shares of the company’s stock valued at $8,555,000 after purchasing an additional 4,087,005 shares in the last quarter. MPM Bioimpact LLC raised its holdings in Compass Therapeutics by 51.9% in the 4th quarter. MPM Bioimpact LLC now owns 8,567,896 shares of the company’s stock worth $12,423,000 after purchasing an additional 2,926,002 shares during the period. SG Americas Securities LLC boosted its position in Compass Therapeutics by 921.6% during the fourth quarter. SG Americas Securities LLC now owns 395,017 shares of the company’s stock worth $573,000 after purchasing an additional 356,352 shares in the last quarter. Finally, JPMorgan Chase & Co. grew its holdings in Compass Therapeutics by 512.5% in the fourth quarter. JPMorgan Chase & Co. now owns 272,328 shares of the company’s stock valued at $395,000 after purchasing an additional 227,864 shares during the period. Institutional investors and hedge funds own 68.43% of the company’s stock.

Compass Therapeutics Company Profile

Compass Therapeutics, Inc, a clinical-stage oncology-focused biopharmaceutical company, engages in developing antibody-based therapeutics to treat various human diseases in the United States. The company's lead product candidates include CTX-009, a bispecific antibody that blocks Delta-like ligand 4 a ligand of Notch-1, and vascular endothelial growth factor A signaling pathways, which are critical to angiogenesis and tumor vascularization; and CTX-471, an IgG4 monoclonal antibody that is an agonist of CD137, a key co-stimulatory receptor on immune cells.